Sanofi Aventis (SNY)

Expect strong market gains heading into the second half of the year. It is a sentiment echoed by research firms on Wall Street in the aftermath of the de-escalation of tensions in the Middle East.

Sanofi (NASDAQ:SNY)  is one of the best low volatility stocks to buy under $50.

Dividends offer investors a reliable source of income, but when it comes to building long-term wealth, capital appreciation has usually done most of the heavy lifting.

On June 18, Tom Lee, Fundstrat's Managing Partner and Head of Research, appeared on CNBC's ‘Closing Bell’ to talk about where stocks are headed from Thursday’s levels.

Is SNY a good stock to buy? We came across a bullish thesis on Sanofi on r/ValueInvesting by stefanliemawan. In this article, we will summarize the bulls’ thesis on SNY.

TheFly reported on May 27 that the US Food and Drug Administration (FDA) has granted priority review to SNY’s New Drug Application for venglustat, an investigational oral glucosylceramide synthase inhibitor...

Haig Bathgate, CEO of Callanish Capital, stated on CNBC on May 7 that he is confident about global stocks despite worries over the Iran war.

Sanofi (NASDAQ:SNY) is one of the best stem cell therapy stocks to buy.

He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...